View Post

Where Cancer-killing T-cells Come From

In In The News by Barbara Jacoby

By: Shirley Dang From: parkerici.org New research published today in Nature Medicine by scientists from the Stanford University School of Medicine and the Parker Institute for Cancer Immunotherapy sheds new light on the origins of tumor-fighting immune cells following immunotherapy treatment with anti-PD-1 checkpoint inhibitors. Using single-cell RNA sequencing technology, the group discovered that T-cells homing in on cancer did …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

The Problem With Miracle Cancer Cures

In In The News by Barbara Jacoby

By: Robert M. Wachter From: nytimes.com I FREQUENTLY care for patients with advanced cancer. A majority have already tried some combination of surgery, chemotherapy and radiation. Many have landed back in the hospital because the cancer has returned or spread widely and left them in intractable pain or struggling to breathe. The hospital stay is often a time when patients …

View Post

Immunotherapy combination effective for patients with rare neuroendocrine cancer

In Clinical Trials by Barbara Jacoby

Source: SWOG From: eurekalert.org A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. Results from the SWOG Cancer Research Network trial known as DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, show …

View Post

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the …

View Post

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

In Clinical Trials by Barbara Jacoby

Provider: Business Wire From: apnews.com Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “ Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion …

View Post

NCCN: Updated Guidelines Reflect Advances, ‘Immunotherapy Era’ for Breast Cancer

In In The News by Barbara Jacoby

By: Bryant Furlow From: cancernetwork.com Updates to the National Comprehensive Cancer Network (NCCN) Guidelines® on breast cancer reflect maturing evidence bases and expanding treatment options, including a recently approved immunotherapy regimen for some patients with locally advanced or metastatic disease, according to speakers at the 2019 NCCN Annual Conference, held March 21–23 in Orlando, Florida. “There are many new and emerging options for …

View Post

Immune Checkpoint Molecule Can Stop Cancer All By Itself

In In The News by Barbara Jacoby

By: News Staff From: science20.com An immune checkpoint molecule, SA-4-1BB developed for cancer immunotherapy also protects against future development of multiple types of cancer when administered by itself, shows a new study. The recombinant protein molecule SA-4-1BBL has been used to enhance the therapeutic efficacy of cancer vaccines with success in pre-clinical animal models. It accomplishes this by boosting the …

View Post

Tomorrow’s breast cancer therapy – today

In Clinical Trials by Barbara Jacoby

By: KATE ANDREWS From: chesterfieldobserver.com From ‘doing less’ to immunotherapy, clinical trials offer patients new options Women in the United States have a 1-in-8 chance of being diagnosed with breast cancer, and the disease has garnered significant attention in recent years, with football players donning pink socks and women running 5K races to raise money for research. And yet, despite …